Congress has passed an omnibus spending bill containing 12 FY22 appropriations bills and additional funding for Ukraine.Â
The Mark Foundation for Cancer Research selected four scientific research projects to receive $12 million in funding for its 2022 Endeavor Awards.Â
Ronald Caplan, founder and president of PMC Property Group, Inc., and his wife Ellen have donated $10 million to the NCI-designated Wistar Cancer Center in Philadelphia, now renamed the Ellen and Ronald Caplan Cancer Center of The Wistar Institute.
The American Cancer Society awarded the University of Illinois Cancer Center a $4.08 million, four-year grant to establish the Illinois Cancer Health Equity Research Center (I-CHER C), a consortium of health care researchers and clinicians charged with improving outcomes in communities disproportionately affected by cancer.
The Prevent Cancer Foundation announced funding for seven scientists who are researching cancer prevention and early detection. Each scientist has been awarded $100,000 for two years.Â
Debbie Weir was named chief executive officer of the Cancer Support Community.
Thermo Fisher Scientific is calling for proposals for its Oncomine Clinical Research Grant. The latest request for submissions will award funding for molecular profiling research that helps accelerate the use of genomic sequencing in oncology.
The NYU Grossman School of Medicine Working Group on Compassionate Use and Preapproval Access will be offering a course, Access to Investigational Medical Products: Clinical Trials, Expanded Access, and Right to Try, at the University of Arizona James E. Rogers College of Law, in partnership with Arizona Law’s Health Law and Policy Program.Â
A study led by researchers from MD Anderson Cancer Center showed a significant overall survival benefit with ribociclib plus endocrine therapy for postmenopausal patients with hormone receptor-positive (HR+) human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer.Â
A UTHealth-led study found increases in both men and women for several HPV-related cancers in low-income counties or those with high smoking rates. Increases were slower in the highest-income U.S. counties, or those with low smoking rates.
